Fingolimod Is Not Effective for Primary-Progressive MS

A randomized trial provides definitive evidence.

Most patients with multiple sclerosis (MS) present with its relapsing form, whereas about 10% to 15% exhibit progressive neurological disability with or without minimal relapse activity – known as primary-progressive MS. Although several licensed therapies can modify the course of relapsing MS, there are currently none for primary-progressive disease.

Fingolimod, an oral sphingosine 1-phosphate receptor modulator effective in relapsing MS, was studied in 970 patients with primary-progressive MS in a multicenter, randomized, double-blind, parallel-group study funded by the manufacturer. Patients between ages 25 and 65 received daily fingolimod or placebo and were monitored for at least 3 years.

The primary outcome was confirmed disability prog…

Reviewing Author

Jeffrey Gelfand, MD

Disclosures

12/1/14I recently attended a trial investigator meeting as a sub-investigator for a clinical trial sponsored by Medimmune.

Jeffrey Gelfand, MD

Disclosures

12/1/14I recently attended a trial investigator meeting as a sub-investigator for a clinical trial sponsored by Medimmune.

Fingolimod Is Not Effective for Primary-Progressive MS

Topics

Reviewing Author